AU2021338837A1 - Methods of treating PDE IV mediated diseases or conditions - Google Patents

Methods of treating PDE IV mediated diseases or conditions Download PDF

Info

Publication number
AU2021338837A1
AU2021338837A1 AU2021338837A AU2021338837A AU2021338837A1 AU 2021338837 A1 AU2021338837 A1 AU 2021338837A1 AU 2021338837 A AU2021338837 A AU 2021338837A AU 2021338837 A AU2021338837 A AU 2021338837A AU 2021338837 A1 AU2021338837 A1 AU 2021338837A1
Authority
AU
Australia
Prior art keywords
compound
condition
pdeiv
formula
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2021338837A
Other languages
English (en)
Inventor
Vuk Koprivica
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vanda Pharmaceuticals Inc
Original Assignee
Vanda Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vanda Pharmaceuticals Inc filed Critical Vanda Pharmaceuticals Inc
Publication of AU2021338837A1 publication Critical patent/AU2021338837A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
AU2021338837A 2020-09-10 2021-09-10 Methods of treating PDE IV mediated diseases or conditions Pending AU2021338837A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063076774P 2020-09-10 2020-09-10
US63/076,774 2020-09-10
PCT/US2021/049870 WO2022056265A1 (en) 2020-09-10 2021-09-10 Methods of treating pde iv-mediated diseases or conditions

Publications (1)

Publication Number Publication Date
AU2021338837A1 true AU2021338837A1 (en) 2023-04-06

Family

ID=78080507

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2021338837A Pending AU2021338837A1 (en) 2020-09-10 2021-09-10 Methods of treating PDE IV mediated diseases or conditions

Country Status (12)

Country Link
US (1) US12622915B2 (enExample)
EP (1) EP4210674A1 (enExample)
JP (2) JP7826294B2 (enExample)
KR (1) KR20230066350A (enExample)
CN (1) CN116507336B (enExample)
AU (1) AU2021338837A1 (enExample)
BR (1) BR112023004214A2 (enExample)
CA (1) CA3191177A1 (enExample)
CL (1) CL2023000648A1 (enExample)
IL (1) IL300628A (enExample)
MX (1) MX2023002539A (enExample)
WO (1) WO2022056265A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2025224045A1 (en) * 2024-02-22 2026-08-06 Vanda Pharmaceuticals, Inc. Treatment of dry eye disease

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0314392A (pt) 2002-09-16 2005-07-12 Glaxo Group Ltd Composto ou um sal do mesmo, composição farmacêutica, uso de um composto, método de tratamento e/ou profilaxia de uma doença inflamatória e/ou alérgica ou deficiência cognitiva em um mamìfero, e, combinação
PL378245A1 (pl) 2003-01-09 2006-03-20 Astellas Pharma Inc. Pochodne pirolopirydazyny
WO2007142929A2 (en) 2006-05-31 2007-12-13 The University Of North Carolina At Chapel Hill Novel pde4 inhibitors
US8080563B2 (en) * 2006-07-07 2011-12-20 Kalypsys Bicyclic heteroaryl inhibitors of PDE4
ES2909316T3 (es) 2015-12-24 2022-05-06 Univ California Reguladores de CFTR y métodos de uso de los mismos
KR20200044873A (ko) 2017-08-24 2020-04-29 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 안구 제약학적 조성물
TWI845795B (zh) * 2019-12-05 2024-06-21 美商汎達製藥公司 眼用醫藥組合物

Also Published As

Publication number Publication date
WO2022056265A1 (en) 2022-03-17
JP2023541261A (ja) 2023-09-29
JP7826294B2 (ja) 2026-03-09
BR112023004214A2 (pt) 2023-04-11
CA3191177A1 (en) 2022-03-17
IL300628A (en) 2023-04-01
US20230364100A1 (en) 2023-11-16
KR20230066350A (ko) 2023-05-15
CN116507336A (zh) 2023-07-28
EP4210674A1 (en) 2023-07-19
CL2023000648A1 (es) 2023-10-13
JP2026102632A (ja) 2026-06-23
MX2023002539A (es) 2023-03-14
US12622915B2 (en) 2026-05-12
CN116507336B (zh) 2026-01-02

Similar Documents

Publication Publication Date Title
KR101217303B1 (ko) 9-치환-8-옥소아데닌 화합물
US10925874B2 (en) Substituted pyrazolopyrimidines as glucocerebrosidase activators
JP6430670B2 (ja) アルドース還元酵素阻害剤および同使用方法
CN103119047B (zh) 三环类蛋白酶体活性增强化合物
CN106967070A (zh) 作为jak抑制剂的化合物
JP2005524612A5 (enExample)
JP2016505040A (ja) アルドース還元酵素阻害剤およびその使用
US20250346591A1 (en) Thiadiazolyl derivatives as dna polymerase theta inhibitors and uses thereof
US12622915B2 (en) Methods of treating PDE IV-mediated diseases or conditions
US20130035321A1 (en) Compounds for the treatment of ocular cancer
JP2025185105A (ja) タンパク質キナーゼ阻害剤としてのヘテロ環化合物の新規塩およびこれらの用途
US20180110784A1 (en) Synthetic tlr4 and tlr7 ligands to prevent, inhibit or treat liver disease
US11925611B2 (en) Use of ZT-1A and analogs thereof to prevent and/or treat neurodegenerative and neurocognitive disorders
US20230097494A1 (en) Deuterated secnidazole for use in the treatment of bacterial vaginosis and methods and uses thereof
EP3618834B1 (en) Functionalized saccharides as anti-inflammatory agents
CN114099509A (zh) 一种酪氨酸激酶抑制剂在制造用以治疗因炎性体激活所致相关疾病的药物中的用途
WO2022021981A1 (zh) 二-(苯并咪唑)-1,2,3-三唑衍生物及其制备和应用
CN109280028B (zh) 喹啉类化合物及其在dpp-4酶抑制剂的应用
CN108888618A (zh) 治疗银屑病的新型药物及其应用
WO2024193509A1 (zh) 苯甲酰基吡咯并嘧啶类衍生物及其用途和制备方法
JP5561648B2 (ja) ロダシアニン誘導体及びリーシュマニア感染症治療用医薬組成物
AU2019359823A1 (en) Quinone reductase 2 inhibitors for use as neuroprotective agents